Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.

摘要: We thank Dr Heldwein and Calado1 Joob Wiwanitkit2 for their interest comments on our paper.3 The authors raised the hypothesis that chronic use of hydroxychloroquine (HCQ) currently approved indications, such as systemic lupus erythematosus (SLE), could have an impact rate COVID-19 possibly clinical course infection. An in vitro antiviral effect HCQ has been demonstrated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence suggests can interfere with virus-receptor binding proliferation, potentially suggesting a prophylactic therapeutic role drug, together advantages its immunomodulatory activity.4 5 Given urgent need to identify efficacious treatment reduce mortality during pandemic, included number national protocols guidelines treat infection, based results preliminary data. Nevertheless, evidence supporting vivo is still …